US4711894A - Stabilized tocopherol in dry, particulate, free-flowing form - Google Patents
Stabilized tocopherol in dry, particulate, free-flowing form Download PDFInfo
- Publication number
- US4711894A US4711894A US06/819,779 US81977986A US4711894A US 4711894 A US4711894 A US 4711894A US 81977986 A US81977986 A US 81977986A US 4711894 A US4711894 A US 4711894A
- Authority
- US
- United States
- Prior art keywords
- tocopherol
- stabilizer
- potency
- vitamin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- This invention relates to potency stabilized tocopherol in a dry, particulate, free-flowing form.
- the stabilized products are in the form of powders or fine granules in which a carrier supports the tocopherol, whose potency is stabilized with certain acid compounds.
- Vitamin E comprises a group of natural substances known as tocopherols. These are fat soluble, closely related chemical compounds found in vegetable oils such as wheat germ oil, soy bean oil and the like. Alpha-tocopherol has the greatest biological activity while its homologs have Vitamin E activity to a lesser extent.
- the tocopherols and their esters are normally water insoluble, oily, waxy or low-melting, which properties generally make them unsuitable for certain pharmaceutical applications, particularly those in which a powder is required such as in tablets or capsules.
- U.S. Pat. No. 3,869,539 assigned to A/S Ferrosan, discloses a method of preparing a dry, particulate, free-flowing form dispersible in cold water of fat-soluble vitamins including Vitamin E. In this method, the vitamins are incorporated in a finely dispersed form in a mass of gelatin.
- the aqueous gelatin solutions must be initially treated with ascorbic acid or mixtures thereof with citric acid, or a mixture of citric acid and sorbose.
- This treatment method is noted as suffering from various drawbacks and the invention disclosed in U.S. Pat. No. 3,869,539 is a method of avoiding such drawbacks through using a mass of gelatin partially decomposed with a base or an inorganic acid, which is then neutralized to a pH value between 4.5 and 7.
- Vitamin E and certain acids have been studied for use as anti-oxidants to protect various materials such as lard and vegetable oils, fatty acids, sardines and arachidonic acid. These studies can be seen from the following literature:
- Vitamin E powders In forming such dry, free-flowing Vitamin E compositions, however, a loss of potency has been recognized. It is important and desirable that the Vitamin E powders contain and maintain a high potency in use.
- the present invention is concerned with a potency stabilized composition in a dry, particulate, free-flowing form which is comprised of Vitamin E incorporated in a carrier whose potency has been stabilized with an effective amount of a certain acid compound.
- potency stabilizing acid compounds are hydroxy acids or amino acids, such as citric acid, ascorbic acid, methionine and cysteine. Citric acid and ascorbic acid have been found to be the most desirable of these acids when employed alone. In admixture with the other amino acids, ascorbic acid with methionine or cysteine is preferred.
- the present invention concerns itself with dry, particulate, free-flowing forms of Vitamin E which are comprised of the active tocopherol compound, a carrier for such tocopherol and a potency stabilizing acid compound employed in an effective amount to stabilize the potency of the tocopherol in the composition.
- the Vitamin E active composition is the free tocopherol form.
- the present invention finds particular utility with the tocopherols which are available in a liquid, oily form.
- the invention is applicable to natural Vitamin E in which the active Vitamin E compound is d- ⁇ -tocopherol as well as synthetic Vitamin E in which d,l- ⁇ -tocopherol is present.
- other homologs such as the beta, gamma, delta and other forms which have Vitamin E activity to a lesser extent.
- compositions in which the ⁇ -tocopherol is present in excess of 85% and preferably in excess of 90% will be employed in this invention.
- the compositions may contain in addition to the Vitamin E, carrier and potency stabilizer acid compound, additional fillers and flow additives to maintain the particulate free-flowing form of the composition.
- the potency stabilizing acid compounds contemplated by the present invention are various hydroxy acids and amino acids. Hydroxy- and amino acids containing from 3 to 6 carbon atoms are particularly desirable. Such hydroxy acids include ascorbic acid and citric acid.
- the amino acids which find utility are methionine and cysteine, which also contain a sulfur atom. Of these acids, ascorbic acid is preferred when employed alone, with citric, cysteine and methionine following in descending order. Where mixtures of the acids are employed, it is preferred that ascorbic acid mixed with citric acid or cysteine.
- the carriers into which will be incorporated the tocopherol compound and the potency stabilizer acid compound are those generally shown in the references discussed earlier.
- Such carriers will include gelatin, silica gel and various starches or gums. Some carriers will also act as flow control agents or such may be incorporated along with the other carriers. Examples of such materials are silicic acid, silicon dioxide, various silicates and silico-aluminate (Zeolite).
- Food grade organic carriers include carbohydrates including gums such as gum Acacia, maltodextrin, as well as gelatin sugar matrixes.
- the composition would comprise from about 20 to about 60% of the Vitamin E active compound and 40 to 80% of a carrier.
- the potency stabilizing acid would be employed in amount of from about 2 to about 50% by weight and preferably from 10 to 50% based on the weight of the total amount of tocopherol compound and stabilizer present in the composition.
- the weight ratio of tocopherol to stabilizer will be on the order of 98:2 to about 1:1, with about 2:1 to 1.5:1 being preferred.
- compositions of the present invention will be prepared in the same manner as the compositions described earlier which the tocopherol compound, the potency stabilizer and the carrier will be formed into an emulsion or slurry and spray dried.
- the emulsion or slurry will be made up to provide a proper spray viscosity to form a product which has a particle size in the range of from below 70, i.e. down to 20-40 microns up to about 900 microns, preferably about 200-500 microns.
- Samples were prepared by coating 6 grams of d- ⁇ -tocopherol (>88% purity) and 1.5 grams of stabilizer candidates on 30 grams silica gel (60-200 mesh) using a laboratory rotary evaporator. After preparation, these were stored in a refrigerator (4° C.) for control and in the hot room (49° C.). After one month, samples were taken from both places and analyzed for weight percent alpha-tocopherol. Likewise, after 2 months storage, the remaining set was sent in for analyses. The stability was determined by calculating relative change: ##EQU1## Results for the relative change are given in Table I. The data show ascorbic acid is best with citric acid being very close for retarding loss of potency, when comparing these to the control to which no stabilizer was added.
- Example II The preparation of samples involved the same weights of materials as Example I. The differences were, first, a narrower and more coarse mesh (35-60 mesh) silica gel was used for the matrix. Second, solvent and water were removed with a vacuum of ⁇ 0.1 mmHg by means of an oil pump. Third, after drying under vacuum was complete, the samples were cooled down and vacuum broken with nitrogen rather than air.
- the constraints were: first, a constant ratio of tocopherol stabilizer coating to the silica gel matrix of 7.5:30, therefore 20% loading; and second, the concentration ranges of the tocopherol compound and stabilizers were: 50-100% (or 3.75 to 7.5 g) for the tocopherol compound and 0-50% (0 to 3.75 g) for the stabilizers.
- Example II The preparation of samples using the same materials was the same as for Example II above, thus 7.5 g of the tocopherol compound alone or with stabilizer(s) were coated on 30 g of silica gel. This was accomplished by first dissolving the tocopherol and stabilizers in a 50/50 mixture of isopropyl alcohol/methanol. Next the solution plus the silica gel (35-60 mesh) were put in a round bottom flask and solvent removed by pulling vacuum ( ⁇ 0.1 mmHg) while rotating in a warm water bath. After drying under vacuum was complete, the samples were cooled down while still under vacuum. The vacuum was broken with nitrogen rather than air. The dried sample preparations were scraped from the flask and mixed thoroughly to be homogeneous. Details as to the composition of the samples can be seen from Table IIIA below.
- ascorbic acid best prevents potency loss, i.e. Runs 18 and 6.
- mixtures of stabilizer a mixture of ascorbic acid and cysteine (Run 13) followed by a mixture of cysteine and citric acid (Run 4) followed in order.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pyrane Compounds (AREA)
- Polyurethanes Or Polyureas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
TABLE I ______________________________________ RELATIVE CHANGE IN D-ALPHA TOCOPHEROL CONTENT Storage Citric Ascorbic Time Control Acid Acid Methionine Cysteine ______________________________________ 1 month -20% -8 -2 -14 -14 2 months -93 -13 -6 -80 -65 ______________________________________
TABLE II ______________________________________ RELATIVE CHANGE IN D-ALPHA- TOCOPHEROL CONTENT Storage Citric Ascorbic Time Control Acid Acid Methionine Cysteine ______________________________________ 1 month -47 -30 +0.8 -8 -42 2 months -53 -39 -9.4 -29 -42 ______________________________________
TABLE III A ______________________________________ Run d-α- Citric Ascorbic Order tocopherol Acid Acid Methionine Cysteine ______________________________________ 1 50 0 0 25 25 2 50 50 0 0 0 3 100 0 0 0 0 4 50 25 0 0 25 5 90 10 0 0 0 6 50 0 25 0 25 7 100 0 0 0 0 8 70 7.5 7.5 7.5 7.5 9 70 0 30 0 0 10 50 25 0 25 0 11 50 25 0 25 0 12 90 0 0 0 10 13 50 0 25 0 25 14 50 25 25 0 0 15 50 0 25 25 0 16 70 30 0 0 0 17 50 0 25 25 0 18 50 0 50 0 0 19 50 0 0 25 25 20 50 0 0 50 0 21 50 0 0 0 50 22 70 0 0 30 0 23 70 7.5 7.5 7.5 7.5 24 90 0 10 0 0 25 50 25 0 0 25 26 70 0 0 30 0 27 70 0 0 0 30 ______________________________________
TABLE III B ______________________________________ ANALYTICAL RESULTS AFTER TWO MONTHS STORAGE Run Wt % α-tocopherol % Order 4° C. 49° C. Loss ______________________________________ 13 6.70 6.50 2.9 4 7.60 6.90 9.2 18 8.00 7.10 11.2 6 7.70 6.80 11.7 14 7.5 6.40 14.7 17 8.30 7.00 15.7 22 10.30 8.60 16.5 8 11.10 9.10 18.0 9 13.30 10.70 19.5 20 7.80 6.20 20.5 15 8.60 6.70 22.1 5 13.40 10.30 23.1 2 7.10 5.30 25.4 23 12.10 9.00 25.6 24 14.90 10.70 28.2 19 7.40 5.30 28.4 23 15.20 10.80 28.9 1 7.00 4.90 30.0 16 10.70 7.40 30.8 25 6.40 4.20 34.4 27 11.70 7.60 35.0 11 6.40 3.80 40.6 3 15.40 9.0 41.6 7 16.40 9.20 43.9 26 14.50 8.00 44.8 21 6.80 3.70 45.6 10 7.50 1.40 81.4 ______________________________________
Claims (8)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/819,779 US4711894A (en) | 1986-01-16 | 1986-01-16 | Stabilized tocopherol in dry, particulate, free-flowing form |
EP87100296A EP0229652B1 (en) | 1986-01-16 | 1987-01-13 | Stabilized tocopherol in dry, particulate, free-flowing form |
ES198787100296T ES2026851T3 (en) | 1986-01-16 | 1987-01-13 | TOCOPHEROL STABILIZED IN A DRY FORM, IN PARTICLES AND FREE FLOWING. |
DE8787100296T DE3774137D1 (en) | 1986-01-16 | 1987-01-13 | STABILIZED TOCOPHEROL IN DRY, FREE-FLOWING PARTICLE FORM. |
AT87100296T ATE68971T1 (en) | 1986-01-16 | 1987-01-13 | STABILIZED TOCOPHEROL IN DRY FREE-FLOWING PARTICLE FORM. |
NO870159A NO173318C (en) | 1986-01-16 | 1987-01-15 | Dry, strength-stabilized, particulate, light-flowing tocopherol preparation |
DK025587A DK169230B1 (en) | 1986-01-16 | 1987-01-16 | Dry, strength-stabilized, particulate, free-flowing tocopherol composition |
JP62008862A JP2677554B2 (en) | 1986-01-16 | 1987-01-16 | Stable tocopherol with a dry, fine-grained surface |
FI870169A FI87524C (en) | 1986-01-16 | 1987-01-16 | Process for preparing a stabilized tocopherol composition in free liquid particulate form |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/819,779 US4711894A (en) | 1986-01-16 | 1986-01-16 | Stabilized tocopherol in dry, particulate, free-flowing form |
Publications (1)
Publication Number | Publication Date |
---|---|
US4711894A true US4711894A (en) | 1987-12-08 |
Family
ID=25229038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/819,779 Expired - Fee Related US4711894A (en) | 1986-01-16 | 1986-01-16 | Stabilized tocopherol in dry, particulate, free-flowing form |
Country Status (9)
Country | Link |
---|---|
US (1) | US4711894A (en) |
EP (1) | EP0229652B1 (en) |
JP (1) | JP2677554B2 (en) |
AT (1) | ATE68971T1 (en) |
DE (1) | DE3774137D1 (en) |
DK (1) | DK169230B1 (en) |
ES (1) | ES2026851T3 (en) |
FI (1) | FI87524C (en) |
NO (1) | NO173318C (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120761A (en) * | 1988-10-14 | 1992-06-09 | Finnan Jeffrey L | Method of making a free-flowing spray dried edible powder comprising an oil |
US5234695A (en) * | 1990-07-24 | 1993-08-10 | Eastman Kodak Company | Water dispersible vitamin E composition |
US5304381A (en) * | 1989-03-17 | 1994-04-19 | Eisai Co., Ltd. | Stabilization of polyprenyl compound |
US6020003A (en) * | 1998-02-23 | 2000-02-01 | Basf Corporation | Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin |
US6303167B1 (en) | 1998-11-09 | 2001-10-16 | Archer-Daniels-Midland Company | Method of producing vitamin powders |
WO2002003972A2 (en) * | 2000-07-11 | 2002-01-17 | Hunter-Fleming Limited | Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
US20040082649A1 (en) * | 1999-11-30 | 2004-04-29 | Mel Rich | Formulation and delivery method to enhance antioxidant potency of Vitamin E |
US20040116512A1 (en) * | 2002-12-17 | 2004-06-17 | Naguib Yousry M.A. | Natural vitamin E compositions with superior antioxidant potency |
WO2007074043A1 (en) * | 2005-12-22 | 2007-07-05 | Basf Se | Method for producing vitamin e-adsorbates |
US20070237834A1 (en) * | 2003-04-18 | 2007-10-11 | Bioderm Research | Zinc Zeolite for the Treatment for Diaper Rash (Diaper Dermatitis) |
US20110020451A1 (en) * | 2009-07-22 | 2011-01-27 | Grunenthal Gmbh | Tamper-resistant dosage form for oxidation-sensitive opioids |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3820693A1 (en) * | 1988-06-18 | 1989-12-21 | Henkel Kgaa | TOPICAL COSMETIC AND PHARMACEUTICAL PREPARATIONS |
EP0476156B1 (en) * | 1990-04-06 | 1996-08-07 | Eisai Co., Ltd. | Solid oral preparation containing catechol compound |
US6613821B2 (en) | 1998-10-09 | 2003-09-02 | Canon Kabushiki Kaisha | Cloth treating agent, cloth, textile printing process and print |
DE10311585A1 (en) * | 2003-03-14 | 2004-09-23 | Basf Ag | Adsorbates for use in human or animal nutrition or cosmetics are produced by introducing material to be adsorbed together with stabilizer on to carrier |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US9247765B2 (en) | 2004-01-14 | 2016-02-02 | Omniactive Health Technologies Limited | Stable beadlets of lipophilic nutrients |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
JP5774853B2 (en) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Pharmaceutical dosage form |
BRPI0912014A2 (en) | 2008-05-09 | 2019-03-06 | Grünenthal GmbH | A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step |
MX2012000317A (en) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form. |
EP2531176B1 (en) | 2010-02-03 | 2016-09-07 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
AR082862A1 (en) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER |
AU2013225106B2 (en) | 2012-02-28 | 2017-11-02 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
WO2014191396A1 (en) | 2013-05-29 | 2014-12-04 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
EA201692388A1 (en) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | DOSAGE FORM AS PARTICLE MULTIPLE, PROTECTED AGAINST CALLED DOSE RESET BY ETHANOL |
WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3608083A (en) * | 1968-06-05 | 1971-09-21 | Hoffmann La Roche | Vitamin e powder |
US3873694A (en) * | 1973-09-27 | 1975-03-25 | Cpc International Inc | Direct compression tabletting composition and pharmaceutical tablets produced therefrom |
JPS53148546A (en) * | 1977-05-31 | 1978-12-25 | Asahi Denka Kogyo Kk | Cosmetic base composition |
JPS56164749A (en) * | 1980-05-22 | 1981-12-17 | Chubu Shiryo Kk | Breeding method of livestock |
US4395422A (en) * | 1981-04-06 | 1983-07-26 | Basf Wyandotte Corporation | Spray dried vitamin E powder |
EP0132821A2 (en) * | 1983-07-25 | 1985-02-13 | Eisai Co., Ltd. | Aqueous solution containing lipid-soluble pharmaceutical substance and a process for preparing the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655852A (en) * | 1969-08-01 | 1972-04-11 | Hoffmann La Roche | Method of forming a stable vitamin e-c granulation |
GB1444024A (en) | 1973-07-20 | 1976-07-28 | Passwaterr A | Food and feed supplents |
FR2244468A1 (en) * | 1973-07-31 | 1975-04-18 | Passwater Richard | Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids |
JPS5421403B2 (en) * | 1974-01-18 | 1979-07-30 | ||
DE3372703D1 (en) * | 1982-10-29 | 1987-09-03 | Crinos Industria Farmaco | Cosmetic preparations promoting the trophism of the skin and of the related hair follicles |
-
1986
- 1986-01-16 US US06/819,779 patent/US4711894A/en not_active Expired - Fee Related
-
1987
- 1987-01-13 ES ES198787100296T patent/ES2026851T3/en not_active Expired - Lifetime
- 1987-01-13 EP EP87100296A patent/EP0229652B1/en not_active Expired - Lifetime
- 1987-01-13 DE DE8787100296T patent/DE3774137D1/en not_active Expired - Lifetime
- 1987-01-13 AT AT87100296T patent/ATE68971T1/en not_active IP Right Cessation
- 1987-01-15 NO NO870159A patent/NO173318C/en unknown
- 1987-01-16 JP JP62008862A patent/JP2677554B2/en not_active Expired - Lifetime
- 1987-01-16 DK DK025587A patent/DK169230B1/en not_active IP Right Cessation
- 1987-01-16 FI FI870169A patent/FI87524C/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3608083A (en) * | 1968-06-05 | 1971-09-21 | Hoffmann La Roche | Vitamin e powder |
US3873694A (en) * | 1973-09-27 | 1975-03-25 | Cpc International Inc | Direct compression tabletting composition and pharmaceutical tablets produced therefrom |
JPS53148546A (en) * | 1977-05-31 | 1978-12-25 | Asahi Denka Kogyo Kk | Cosmetic base composition |
JPS56164749A (en) * | 1980-05-22 | 1981-12-17 | Chubu Shiryo Kk | Breeding method of livestock |
US4395422A (en) * | 1981-04-06 | 1983-07-26 | Basf Wyandotte Corporation | Spray dried vitamin E powder |
EP0132821A2 (en) * | 1983-07-25 | 1985-02-13 | Eisai Co., Ltd. | Aqueous solution containing lipid-soluble pharmaceutical substance and a process for preparing the same |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120761A (en) * | 1988-10-14 | 1992-06-09 | Finnan Jeffrey L | Method of making a free-flowing spray dried edible powder comprising an oil |
US5304381A (en) * | 1989-03-17 | 1994-04-19 | Eisai Co., Ltd. | Stabilization of polyprenyl compound |
US5234695A (en) * | 1990-07-24 | 1993-08-10 | Eastman Kodak Company | Water dispersible vitamin E composition |
US6020003A (en) * | 1998-02-23 | 2000-02-01 | Basf Corporation | Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin |
US6303167B1 (en) | 1998-11-09 | 2001-10-16 | Archer-Daniels-Midland Company | Method of producing vitamin powders |
US20020001622A1 (en) * | 1998-11-09 | 2002-01-03 | Morris Charles A. | Method of producing vitamin powders |
US8013013B2 (en) | 1999-11-30 | 2011-09-06 | Soft Gel Technologies, Inc. | Formulation and delivery method to enhance antioxidant potency of vitamin E |
US20060105034A1 (en) * | 1999-11-30 | 2006-05-18 | Mel Rich | Formulation and delivery method to enhance antioxidant potency of Vitamin E |
US7015245B2 (en) | 1999-11-30 | 2006-03-21 | Melvin Rich | Formulation to enhance antioxidant potency of Vitamin E |
US20060106093A1 (en) * | 1999-11-30 | 2006-05-18 | Mel Rich | Formulation and delivery method to enhance antioxidant potency of Vitamin E |
US20040082649A1 (en) * | 1999-11-30 | 2004-04-29 | Mel Rich | Formulation and delivery method to enhance antioxidant potency of Vitamin E |
US20040106674A1 (en) * | 1999-11-30 | 2004-06-03 | Melvin Rich | Formulation and delivery method to enhance antioxidant potency of vitamin E |
US8110600B2 (en) | 1999-11-30 | 2012-02-07 | Soft Gel Technologies, Inc. | Formulation and delivery method to enhance antioxidant potency of vitamin E |
US7012092B2 (en) | 1999-11-30 | 2006-03-14 | Mel Rich | Formulation and delivery method to enhance antioxidant potency of Vitamin E |
WO2002003972A3 (en) * | 2000-07-11 | 2002-10-24 | Hunter Fleming Ltd | Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
US20040033936A1 (en) * | 2000-07-11 | 2004-02-19 | Ernst Wulfert | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
WO2002004025A1 (en) * | 2000-07-11 | 2002-01-17 | Hunter-Fleming Limited | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
WO2002003972A2 (en) * | 2000-07-11 | 2002-01-17 | Hunter-Fleming Limited | Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
US7329688B2 (en) | 2002-12-17 | 2008-02-12 | Soft Gel Technologies, Inc. | Natural vitamin E compositions with superior antioxidant potency |
US20040116512A1 (en) * | 2002-12-17 | 2004-06-17 | Naguib Yousry M.A. | Natural vitamin E compositions with superior antioxidant potency |
US7449491B2 (en) | 2002-12-17 | 2008-11-11 | Soft Gel Technologies, Inc. | Natural vitamin E compositions with superior antioxidant potency |
US20090156664A1 (en) * | 2002-12-17 | 2009-06-18 | Soft Gel Technologies, Inc. | Natural Vitamin E Compositions with Superior Antioxidant Potency |
US7989493B2 (en) | 2002-12-17 | 2011-08-02 | Soft Gel Technologies, Inc. | Natural vitamin E compositions with superior antioxidant potency |
US20060093664A1 (en) * | 2002-12-17 | 2006-05-04 | Soft Gel Technologies, Inc. | Natural vitamin E compositions with superior antioxidant potency |
US20070237834A1 (en) * | 2003-04-18 | 2007-10-11 | Bioderm Research | Zinc Zeolite for the Treatment for Diaper Rash (Diaper Dermatitis) |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
WO2007074043A1 (en) * | 2005-12-22 | 2007-07-05 | Basf Se | Method for producing vitamin e-adsorbates |
US20080293955A1 (en) * | 2005-12-22 | 2008-11-27 | Basf Se | Method for Producing Vitamin E-Adsorbates |
US20110020451A1 (en) * | 2009-07-22 | 2011-01-27 | Grunenthal Gmbh | Tamper-resistant dosage form for oxidation-sensitive opioids |
US10493033B2 (en) * | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Also Published As
Publication number | Publication date |
---|---|
ES2026851T3 (en) | 1992-05-16 |
DK25587A (en) | 1987-07-17 |
EP0229652A2 (en) | 1987-07-22 |
FI87524B (en) | 1992-10-15 |
ATE68971T1 (en) | 1991-11-15 |
JP2677554B2 (en) | 1997-11-17 |
NO870159L (en) | 1987-07-17 |
NO173318C (en) | 1993-12-01 |
EP0229652B1 (en) | 1991-10-30 |
FI870169A (en) | 1987-07-17 |
FI87524C (en) | 1993-01-25 |
JPS62190181A (en) | 1987-08-20 |
NO173318B (en) | 1993-08-23 |
DK169230B1 (en) | 1994-09-19 |
NO870159D0 (en) | 1987-01-15 |
FI870169A0 (en) | 1987-01-16 |
EP0229652A3 (en) | 1987-10-14 |
DK25587D0 (en) | 1987-01-16 |
DE3774137D1 (en) | 1991-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4711894A (en) | Stabilized tocopherol in dry, particulate, free-flowing form | |
US5179122A (en) | Nutritional supplement containing vitamin e | |
US5234695A (en) | Water dispersible vitamin E composition | |
US3608083A (en) | Vitamin e powder | |
US3932634A (en) | High potency vitamin water dispersible formulations | |
KR20010033917A (en) | Powders containing tocotrienols, process for producing the same and tablets prepared by compression molding the same | |
JP2922967B2 (en) | Composition of vitamin B group compound and method for producing the same | |
US6303167B1 (en) | Method of producing vitamin powders | |
WO2018133833A1 (en) | Stable and liposoluble active ingredient composition, microcapsule, and preparation method and application thereof | |
NO155716B (en) | Apparatus for leakage detection of cryogenic materials. | |
US4187322A (en) | Powder compositions containing vitamin C active component | |
US2855306A (en) | Fat-soluble vitamin composition | |
US3252864A (en) | Stable fat-soluble vitamin-containing compositions | |
US6071963A (en) | Water dispersible compositions | |
US3708583A (en) | Stabilized vitamin a additive | |
US3458637A (en) | Compositions stabilized with tocopheramine antioxidants | |
GB2120935A (en) | Fat-soluble vitamin preparation | |
US12213498B2 (en) | Storage stable mixtures | |
US2895878A (en) | Compositions containing stabilized vitamin a materials | |
AU2018387681B2 (en) | Storage stable mixtures, method of improving retention of a compound and use of rice hulls and/or rice bran to enhance retention of a compound | |
CA1210697A (en) | Free-flowing, high density, non-agglomerated fat- soluble vitamin powders | |
US20240324626A1 (en) | Methods of forming storage stable mixtures | |
WO2001091576A1 (en) | Granular vitamin composition | |
BR112020012061B1 (en) | STORAGE STABLE MIXTURE, USE OF RICE HULL AND/OR RICE BRAN AND METHOD FOR IMPROVING RETENTION OF 1,3-PROPANEDIOL MONONITRATE | |
WO2019121502A1 (en) | Storage stable mixtures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HENKEL CORPORATION A CORP OF DE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:WENZEL, BRUCE E.;CLARK, JAMES P.;REEL/FRAME:004508/0750 Effective date: 19860116 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19991208 |
|
AS | Assignment |
Owner name: COGNIS CORPORATION, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HENKEL CORPORATION;REEL/FRAME:011356/0442 Effective date: 19991217 |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |